- Solid Biosciences ( NASDAQ: SLDB ) and Phlox Therapeutics entered a strategic collaboration to develop precision medicines for genetic cardiac diseases.
- The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM).
- The strategic collaboration will integrate Solid's vector biology, manufacturing capabilities and drug development experience with Phlox's expertise in genetic cardiomyopathies and RNA therapeutics.
- The companies said they will collaborate to develop novel precision genetic medicines for this form of DCM.
- The collaboration will also be supported in part by a grant from the Dutch Top Sector Life Sciences and Health, a coalition for public-private research.
- SLDB +0.84% to $6 premarket Jan. 11
For further details see:
Solid Biosciences, Phlox team up to develop precision drugs for heart diseases